| Christopher Yee, MD | |
|
3828 Schaufele Ave Ste 200, Long Beach, CA 90808-1793 | |
| (657) 241-8990 | |
| Not Available |
| Full Name | Christopher Yee |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 14 Years |
| Location | 3828 Schaufele Ave Ste 200, Long Beach, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891012860 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A117582 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Long Beach Memorial Medical Center | Long beach, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Memorialcare Medical Foundation | 8729277314 | 382 |
News Archive
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim's® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Having a fat head may not be a bad thing, according to new findings at The Johns Hopkins University. As reported in the February 9 issue of Neuron, researchers have made a significant discovery as to how adding fat molecules to proteins can influence the brain circuitry controlling cognitive function, including learning and memory.
› Verified 5 days ago
| Entity Name | Memorialcare Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205167350 PECOS PAC ID: 8729277314 Enrollment ID: O20110113000219 |
News Archive
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim's® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Having a fat head may not be a bad thing, according to new findings at The Johns Hopkins University. As reported in the February 9 issue of Neuron, researchers have made a significant discovery as to how adding fat molecules to proteins can influence the brain circuitry controlling cognitive function, including learning and memory.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Yee, MD 3828 Schaufele Ave Ste 200, Long Beach, CA 90808-1793 Ph: (657) 241-8990 | Christopher Yee, MD 3828 Schaufele Ave Ste 200, Long Beach, CA 90808-1793 Ph: (657) 241-8990 |
News Archive
The incidence and prevalence of inflammatory bowel disease (IBD) are increasing with time and in different regions around the world, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.
LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim's® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.
Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
Having a fat head may not be a bad thing, according to new findings at The Johns Hopkins University. As reported in the February 9 issue of Neuron, researchers have made a significant discovery as to how adding fat molecules to proteins can influence the brain circuitry controlling cognitive function, including learning and memory.
› Verified 5 days ago
Sohrab Tanavoli, D.O Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 5901 E 7th St, Long Beach, CA 90822 Phone: 562-826-8000 | |
Ngoc-tram Gia Tran, D.O Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2888 Long Beach Blvd Ste 235, Long Beach, CA 90806 Phone: 562-803-2486 | |
Michael A Raya, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2600 Redondo Ave, Long Beach, CA 90806 Phone: 562-988-7000 | |
Meggan Chappell, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3833 Worsham Ave Ste 300, Long Beach, CA 90808 Phone: 562-595-5421 Fax: 562-426-2862 | |
Dr. Maurice A Bell, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4100 Long Beach Blvd, Suite 200, Long Beach, CA 90807 Phone: 562-981-2355 Fax: 562-981-2920 | |
Katya C Corado, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 1333 Chestnut Ave, Long Beach, CA 90813 Phone: 562-599-8601 Fax: 562-218-0853 | |
Dr. Diane L. Johnson, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 65 Pine Ave, #19, Long Beach, CA 90802 Phone: 714-402-4685 Fax: 562-856-0389 |